Logo: to the web site of Uppsala University

uu.sePublications from Uppsala University
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Number of risk factors versus infection after transrectal prostate biopsy: a nationwide population-based study
Reg Kronoberg, Dept Surg, Växjö, Sweden;;Univ Göteborg, Inst Clin Sci, Sahlgrenska Acad, Dept Urol, Göteborg, Sweden;;Växjö Reg Hosp, SE-35185 Växjö, Sweden.
Reg Kronoberg, Dept Infect Dis, Växjö, Sweden;;Lund Univ, Dept Translat Med, Malmö, Sweden;.
Univ Göteborg, Inst Clin Sci, Sahlgrenska Acad, Dept Urol, Göteborg, Sweden;;Sahlgrenska Univ Hosp, Dept Orthopaed, Göteborg, Sweden;.
Univ Göteborg, Inst Clin Sci, Sahlgrenska Acad, Dept Urol, Göteborg, Sweden;;Sahlgrenska Univ Hosp, Dept Orthopaed, Göteborg, Sweden;.
Show others and affiliations
2026 (English)In: Scandinavian journal of urology, ISSN 2168-1805, E-ISSN 2168-1813, Vol. 61, p. 99-105Article in journal (Refereed) Published
Abstract [en]

Objective: It is unknown how risk factors for infection after transrectal prostate biopsy interact. We designed a study to evaluate this. Methods: We identified biopsy procedures from 2006 to 2020 in the Swedish nationwide database PCBaSe. Primary outcome was post-biopsy infection, defined as a dispensed prescription ofa urinary tract antibiotic and secondary outcome was inpatient care for infection both within 30 days. Riskfactors were age, diabetes, medical treatment of lower urinary tract symptoms (LUTSs), prostate enlargement, immunosuppressives, corticosteroids, and defined antibiotic exposure during the past 1-12 months. When analysing risk in men with several risk factors clinically related factors were grouped as urinary tract infection (UTI)-antibiotics, treatment of LUTS, immunosuppressives including corticosteroids, and diabetes. Logistic regression was used to calculate odds ratios (ORs) with 95% confidence intervals (CI). Results: A total of 139,056 transrectal prostate biopsy procedures were analysed. The grouped risk factors were significantly associated with post-biopsy infection (multivariable ORs: 1.22-1.72). Infection increased with number of risk factors; none: 4.0% (95% CI: 3.8-4.1), one: 6% (95% CI: 5.9-6.4), two: 10% (95% CI: 9.3-11), and three or four: 12% (95% CI: 9.8-14); inpatient care increased from 2.0% (95% CI: 1.9-2.1) to 3.1% (95% CI: 2.2-4.4). Conclusion: Infection risk after transrectal prostate biopsy incrementally increases with the number of risk factors. Clinical Implications: The transrectal biopsy route should be used with caution for patients with several risk factors for post-biopsy infections. Patient Summary: Diabetes, urinary symptoms, previous urinary infection, and immune suppressing medication increase the risk of infection after a prostate biopsy through the rectum. Patients with many of these conditions have a particularly high risk. What does the study add? We used nationwide register data to estimate the infection risk after transrectal prostate biopsy by the number of these risk factors: diabetes, medical treatment of lower urinary tract symptoms, immunosuppressives including corticosteroids, and use of urinary tract antibiotics the past year. The risk incrementally increased from 4.0% in men with no risk factor to 12% in those with 3 or 4. Take Home Message: Infection after transrectal prostate biopsy increases with number of risk factors: diabetes, medical treatment of lower urinary tract symptoms, immunosuppressives including corticosteroids, and use of urinary tract antibiotics the past year, from 4.0% (none) to 12% (3 or 4).

Place, publisher, year, edition, pages
MJS Publishing, 2026. Vol. 61, p. 99-105
Keywords [en]
Prostate biopsy, transrectal, complication, risk factor, infection
National Category
Clinical Medicine
Identifiers
URN: urn:nbn:se:uu:diva-585036DOI: 10.2340/sju.v61.45581ISI: 001740787500003PubMedID: 41914521Scopus ID: 2-s2.0-105034704778OAI: oai:DiVA.org:uu-585036DiVA, id: diva2:2056586
Available from: 2026-04-29 Created: 2026-04-29 Last updated: 2026-04-29Bibliographically approved

Open Access in DiVA

fulltext(471 kB)70 downloads
File information
File name FULLTEXT01.pdfFile size 471 kBChecksum SHA-512
bc07fe6fbb7ed2e9162791b1fdef90d8c89dd0a3e278f8ec679f89b7f53d47ed9a7e64b1dabbbea7d07d18b094333e064ecb949e342c16a1d81f05149f28ddd4
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMedScopus

Authority records

Stattin, Pär

Search in DiVA

By author/editor
Stattin, Pär
By organisation
Urology
In the same journal
Scandinavian journal of urology
Clinical Medicine

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 251 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf